Life Sciences Times

Merck’s KEYTRUDA-Padcev Combo Improves Survival for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients in Phase 3 Trial

Akamis Bio Appoints C4 Therapeutics CEO Andrew Hirsch to Board of Directors

BostonGene Study Validates Multimodal RNA and DNA Assay for Precision Oncology

PureTech Launches Celea Therapeutics to Advance Treatment of Serious Respiratory Diseases

Trinity Life Sciences Unveils Digital Affinity Platform to Enhance HCP Engagement

VideaHealth Lands No. 28 Spot on 2025 Inc. 5000 Fastest-Growing Companies List

First FDA-Approved Treatment for MacTel Administered Following Commercial Launch

Study Points to New Mechanism for Schizophrenia Drug Candidate Evenamide

FDA Clears Thermo Fisher Test to Match Lung Cancer Patients With Newly Approved HER2-Targeted Drug

SetPoint Medical Secures $140 Million to Advance Rheumatoid Arthritis Therapy, Expands Leadership Team